Pfizer will share a portion of revenue with the U.S. Department of Health and Human Services (HHS). This applies if the company charges higher prices for its drugs in overseas markets.
A consumer watchdog group obtained the contract through a Freedom of Information Act lawsuit, making the agreement public.
The provision is part of a "most favored nation" pricing deal, effective from January 2026 through January 2029.
The White House states the revenue collected by HHS aims to lower costs for American patients and taxpayers. It also aims to shift some of the burden of pharmaceutical innovation to other countries.
Specifics such as the revenue-sharing percentage and the drugs covered remain redacted in the released documents.